Folicard

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Folicard

What is Folicard? Overview

Property Description
Active Ingredient Folic Acid (Pteroylglutamic acid)
Form Oral Solid Preparation (Tablet)
Pharmacological Class Hematopoietic Agent, B-group Vitamin
General Purpose Correcting Nutritional Deficiency
Origin Synthetic Vitamin

What Type of Medicine is Folicard?

Folicard is a pharmaceutical preparation containing the essential micronutrient Folic Acid, classified primarily as a B-group vitamin and a hematopoietic agent. It is typically available as a monocomponent product presented as an oral solid preparation, specifically in tablet form. Folic Acid is a water-soluble B-vitamin essential for red blood cell formation and for its role in cell division.


Composition and Origin: Is Folicard the Same as Folate?

The active ingredient in Folicard is Folic Acid (Pteroylglutamic acid), which is the synthetic vitamin form produced through chemical processes. This form is distinct from folate, the naturally occurring B₉ found in foods, by its structure, requiring the body to convert it into its biologically active state. Folic Acid is utilized globally in the prevention and treatment of deficiencies associated with its essential metabolic role. Folicard tablets contain this single active ingredient combined with standard solid pharmaceutical excipients suitable for oral ingestion.


What is the General Purpose of Folicard?

The general purpose of Folicard is to provide the body with a critical nutrient that is essential for fundamental life processes, thereby helping to prevent or correct nutritional deficiencies. Folic Acid acts as an indispensable cofactor precursor for the synthesis of DNA and RNA—the genetic blueprints for all new cells—and is crucial for the proper and healthy maturation of red blood cells (erythropoiesis). By supporting this cellular machinery, Folicard promotes overall cellular integrity and blood health.

Regulatory References

  1. confirmed by the National Institutes of Health

What side effects are possible with Folicard?

Possible Side Effects and Safety Information

The safety profile of Folicard (Folic Acid) is defined by a low incidence of adverse reactions, but is subject to a critical safety constraint outlined in regulatory documentation concerning specific blood disorders.

Officially Documented Adverse Reactions

The majority of adverse reactions are categorized as Rare or Frequency Not Known across official regulatory labels. These reactions primarily involve four system-organ classes:

  • Immune System Disorders: Allergic sensitization, which may manifest as skin rash, itching (pruritus), or hives (urticaria). Serious allergic reactions, including anaphylaxis and severe respiratory difficulty, have been documented, though rarely.
  • Gastrointestinal Disorders: Reported effects include anorexia (loss of appetite), nausea, flatulence, and abdominal distension.
  • Nervous System/Psychiatric Disorders: In some cases, regulatory documents note the potential for irritability, altered sleep patterns, excitement, or general malaise.

Critical Safety Constraints

The most significant safety restriction for Folicard is its use in individuals with undiagnosed or untreated pernicious anemia or other megaloblastic anemias caused by Vitamin B₁₂ deficiency. Regulatory bodies stipulate that Folic Acid supplementation must not be used alone in these cases. The official concern is that Folic Acid may correct the hematological symptoms of the anemia while allowing the underlying neurological damage associated with B₁₂ deficiency to progress unchecked. This risk of masking neurological symptoms is a primary constraint governing long-term therapy and higher doses.

Population-Specific Notes

The official label includes a safety constraint for patients with epilepsy receiving certain anticonvulsant drugs, as Folic Acid has been reported to potentially interfere with the effectiveness of these medications.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information classifies Folicard (Folic Acid) as having low acute toxicity, meaning that overdose is generally considered unlikely to cause serious systemic adverse effects. Acute overdose management is typically limited to symptomatic and supportive treatment, as no specific antidote is known according to regulatory documents.

Documented Manifestations and Emergency Action

Classification Official Regulatory Statement
Overdose Presentation Acute overdose is considered nontoxic. Manifestations of excessive chronic intake (e.g., prolonged high-dose exposure) may include non-specific gastrointestinal disturbances (such as nausea or abdominal distention) and neuropsychological changes (such as altered sleep patterns or confusion).
Required Emergency Action Immediate medical attention must be sought for signs of a severe allergic reaction, which constitutes the primary serious outcome documented in official labels.
Help-Seeking Triggers Seek immediate medical attention for specific signs of allergic sensitization, including hives, rash, itching, difficulty breathing, or swelling of the face, lips, tongue, or throat.

This profile defines the emergency response for Folicard by focusing on the recognition of severe allergic symptoms, which are the main documented complication requiring urgent medical intervention, rather than toxicity from acute over-ingestion.

Therapeutic Uses of Folicard

Folicard (Folic Acid) is generally used across key therapeutic areas to address deficiencies and provide essential support, contributing to symptomatic relief and preventative benefits. The use is commonly applied when there is a need to address nutritional inadequacy or periods of increased physiological demand.


The main applications involve managing megaloblastic and macrocytic anemias, offering supportive assistance during the periconceptional period for fetal development, and addressing deficiencies linked to gastrointestinal malabsorption disorders or chronic alcoholism.

Addressing Fatigue and Deficiency Symptoms

Folicard is commonly used to help manage the systemic symptom cluster of chronic fatigue, generalized weakness, and lack of energy associated with deficiency-related blood disorders. By supporting the healthy production of blood cells, Folicard generally helps with easing the overall symptom load of fatigue and weakness, which assists with maintaining functional stability in daily life. This intervention is significant as folic acid supplementation is a recognized factor in supporting the development of the central nervous system.

Supporting Fetal Health and Complex Scenarios

A relevant application is preventative support during early pregnancy, helping to reduce the risk of major congenital abnormalities, known as Neural Tube Defects (NTDs). Furthermore, in complex clinical scenarios, Folicard provides supportive therapeutic benefit by managing the systemic effects of deficiency, which may assist with secondary manifestations such as oral discomfort (glossitis) and irritability.


Quick Fact: Relief for Chronic Fatigue
Folicard is commonly used to help manage the pervasive weakness and tiredness that often cluster together as the primary symptoms of nutritional deficiency anemia.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Folicard?

This section describes the official population eligibility and non-eligibility rules for Folicard (Folic Acid) based strictly on governmental regulatory documents.


Eligibility Scope

Classification Population Status Summary
Absolute Contraindication Untreated Cobalamin (Vitamin B12) Deficiency Must not be used alone; risk of masking symptoms while irreversible neurological damage progresses.
Contraindication Known Hypersensitivity Prohibited in patients with a known allergy to Folic Acid or excipients.
Established Use Adults, Children, Older Adults Permitted for deficiency treatment and prophylaxis across all age groups.
Established Use Pregnancy and Lactation Permitted for deficiency and Neural Tube Defect prophylaxis; no known hazards when used appropriately.
Conditional Use Malignant Disease Contraindicated unless the megaloblastic anemia is confirmed to be due to folic acid deficiency.

Folicard is generally established for use in all age populations, but the most critical restriction is the Absolute Contraindication against use in patients with untreated B12 deficiency.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Folicard (Folic Acid) exhibits documented interaction patterns that are classified by regulatory authorities based on pharmacodynamic and pharmacokinetic outcomes, as well as constraints concerning administration timing.

Documented Interaction Patterns

Interaction Type Interacting Substances Official Regulatory Outcome
Pharmacodynamic Antagonism Methotrexate, Pyrimethamine, Trimethoprim Co-administration may result in mutual inhibition of therapeutic effects, as Folic Acid competes with these antifolate agents.
Exposure Modification Phenytoin, Primidone, Barbiturates Folic Acid supplementation is officially associated with decreased serum levels of these antiepileptic drugs.
Absorption Interference Cholestyramine, Antacids (Aluminium/Magnesium) These agents can impair Folic Acid absorption, requiring separation of administration by specific time intervals.

Co-administration with Chloramphenicol may hinder the response to Folicard treatment, and Folic Acid may inhibit the action of Zinc supplements. Regulatory documents note that alcohol consumption can interfere with folate metabolism. The medicine is restricted from use as the sole therapeutic agent in undiagnosed megaloblastic anemia to prevent the masking of hematological symptoms of Vitamin B12 deficiency. This exposure-modifying effect is a critical note for patients with epilepsy, due to the associated risk of increased seizure frequency.

Mechanism of Action

How Folicard Works

The mechanism of Folicard (Folic Acid) defines the core biochemical function within cell replication and amino acid recycling pathways.


Conversion, Activation, and Cofactor Provision

Folicard's active ingredient, Folic Acid, is an inactive synthetic compound that requires mandatory internal processing to become biologically functional. This activation involves a sequential reduction reaction catalyzed by the enzyme Dihydrofolate Reductase (DHFR) to yield Tetrahydrofolate (THF) derivatives. This conversion is the entry point into the body's One-Carbon Metabolism pathway, providing the cofactors necessary to drive downstream biosynthesis reactions.


Support for DNA Synthesis and Cell Proliferation

The primary mechanistic domain involves the active folate coenzymes donating single-carbon units to enzymes like Thymidylate Synthase. This action is crucial for producing the DNA components purines and thymidylate. By enabling the synthesis of DNA components, the mechanism allows for the mitotic division and maturation of rapidly proliferating cells, particularly erythroblasts in the bone marrow.


Homocysteine Regulation and Metabolic Interdependence

Active folates are necessary for the enzyme Methionine Synthase to convert Homocysteine back into Methionine, which contributes to the regulation of amino acid metabolism. This key reaction, however, is mechanistically dependent on the coenzyme Vitamin B12 (Cobalamin). Folic Acid’s mechanistic participation in this pathway is functionally limited by the availability of B12.

Dosage and Administration Information

How to Use Folicard: Official Administration Guidelines

Folicard, which contains Folic Acid, is used according to specific administration rules. The primary method of administration for the Folicard tablet is oral (PO). Parenteral routes, such as intravenous (IV) or intramuscular (IM) injection, are typically reserved for Folic Acid solutions when the patient experiences severe malabsorption or is otherwise unable to tolerate oral intake.

The official dosage structure defines distinct regimens for therapeutic correction versus maintenance or prophylaxis. The medicine is commonly administered once daily.

Dosing and Frequency Patterns

Dosing Pattern Typical Daily Dose Range Contextual Frequency
Therapeutic Correction Up to 1 mg daily; up to 5 mg daily for specific cases Once daily
Routine Maintenance 0.4 mg to 1 mg daily Once daily
High-Risk Prophylaxis 4 mg (4000 µg) daily Once daily

For prophylaxis against certain congenital abnormalities, the 4 mg regimen is typically scheduled to begin prior to conception and continue through the early stages of pregnancy. Pediatric dosing is based on age and weight, ranging from 0.1 mg to 1 mg daily.

Tablets may be taken with or without food and are to be swallowed whole with water. Administration must be separated from certain other medications by one to four hours to ensure optimal absorption.

Recent Clinical Evidence

Research evidence / Overview of Studies for Folicard (Folic Acid)


Evidence for Preventing Neural Tube Defects (NTDs)

The research supporting the use of Folicard (Folic Acid) is based on a high-level body of evidence, including foundational Randomized Controlled Trials (RCTs) conducted before mandatory food fortification, which were followed by extensive Systematic Reviews and Meta-analyses. These studies focused on women who were planning or capable of pregnancy, examining the use of Folicard (Folic Acid) during the periconceptional period, exploring its association with the prevalence of major congenital abnormalities. Findings from the evidence base generally described a pattern of lower reported rates of NTD occurrence associated with the use of folic acid during the periconceptional period.

Despite the existing research base, new, large-scale, placebo-controlled RCTs are rarely conducted due to ethical constraints, as intervention is now standard practice in many regions. The post-fortification environment also means that subsequent observational studies may show findings that differ from pre-fortification trials due to higher baseline folate status in the general population.


Evidence for Treating Folate Deficiency Anemia

Evidence for the use of Folicard in evaluating the physiological effects on hematological changes and systemic symptoms associated with megaloblastic anemia is supported by an existing body of evidence and includes historical clinical trials and case series. These studies were applied in populations of adults and children with a confirmed diagnosis of megaloblastic anemia caused by a lack of folate. Research examined outcomes related to systemic or functional imbalance, such as patterns of generalized weakness and chronic fatigue reported during the study period, as well as objective hematological outcomes.

Studies monitored physiological strain by measuring shifts in key blood cell parameters. Research documented patterns related to the evolution of blood markers, including hemoglobin levels and red blood cell size (MCV), which typically reflect changes in the production of red blood cells. Because the physiological effect of Folicard in deficiency is generally accepted by the scientific community, few modern, double-blind RCTs have been conducted. The evidence relies heavily on clear hematological endpoints that describe a physiological change in the deficiency state.


Research Gaps and Uncertainty

One key research limitation frame is the difficulty in studying the effects of Folicard in modern populations due to the widespread nature of food fortification, which can complicate the study of supplementation alone. Furthermore, long-term effects are not fully established, particularly regarding non-NTD outcomes and the extended health status of offspring. The evidence quality varies across studies, and many findings were mixed or derived from observational settings, highlighting the need for continued, robust research to address these areas of remaining uncertainty.

Key Studies & References

  1. Folic Acid for the Prevention of Neural Tube Defects: US Preventive Services Task Force Recommendation Statement
  2. Megaloblastic Anemia - StatPearls - NCBI Bookshelf (Clinical Overview and Management)
  3. Folate Deficiency (Merck Manual Professional Edition)

Frequently Asked Questions (FAQ)

Common questions about Folicard (FAQ)


Q: Can Folicard be taken long-term?

A: Folic Acid, the active ingredient in Folicard, is described in regulatory documents as relatively nontoxic in humans. However, prolonged or high-dose therapy may be associated with decreased Vitamin B₁₂ serum levels. Due to this concern, the medicine must not be used alone in patients with undiagnosed Vitamin B₁₂ deficiency to prevent masking the neurological symptoms of that condition.


Q: Is there a known time limit for how long someone should use Folicard?

A: Regulatory guidance defines the length of treatment for specific conditions, such as until blood symptoms normalize in megaloblastic anemia. For prophylactic uses (like prevention before and during early pregnancy), a specific timeline is also established. Official product information does not set a universal upper limit on the duration of use, but constraints exist for long-term use related to Vitamin B₁₂ status.


Q: Can Folicard affect lab test results?

A: Yes, official product information indicates Folicard may be associated with some changes in lab readings. Prolonged therapy is associated with decreased Vitamin B₁₂ serum levels. Additionally, Folicard may be associated with 'false low serum and red cell folate levels' if antibiotics are being co-administered.


Q: Does Folicard interact with common pain relievers?

A: Official guidance from authoritative sources notes that Folicard is not typically listed as interacting with common, everyday pain relievers like paracetamol. However, for patients taking methotrexate, authoritative sources advise checking with a healthcare provider before using non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen.


Q: Does alcohol consumption impact how Folicard works?

A: Regulatory documents state that alcohol consumption is associated with interference with the body's folate metabolism. This may increase the rate at which Folic Acid is eliminated from the body. Excessive alcohol intake is also noted as a potential cause of folate deficiency.


Q: Can Folicard affect mood or anxiety levels?

A: Folic Acid is associated with effects on the central nervous system when used in high doses. Officially reported effects, particularly at doses of 15 mg daily, include mental depression, confusion, excitement, irritability, and impaired judgment.


Q: What happens in the body when Folicard is absorbed?

A: According to the clinical pharmacology sections of official labels, Folic Acid is absorbed quickly from the small intestine after being swallowed. It generally appears in the blood plasma about 15 to 30 minutes after an oral dose, with the highest blood levels typically reached within one hour.


Q: Can Folicard be split in half if the tablet is too large?

A: Official administration guidance for Folicard describes that the tablets are to be swallowed whole. Regulatory labels do not contain information authorizing or detailing how to split the tablet, as this could affect the intended action of the medication.


Q: Does Folicard help with energy levels?

A: Official information describes Folicard's role in treating megaloblastic anemia due to folate deficiency, a condition that can cause symptoms like generalized weakness and chronic fatigue. Correction of the underlying deficiency is the mechanism by which relief from these deficiency-related symptoms is typically observed.


Q: Can Folicard cause sleepiness or insomnia?

A: Adverse reactions have been reported in patients receiving high doses of Folic Acid, specifically mentioning altered sleep patterns. These altered patterns may be associated with difficulty sleeping or concentrating.


Q: Is Folicard safe for older adults?

A: Official indications state that Folicard is established for use in adults, including older adults, for the treatment of megaloblastic anemia due to folate deficiency. Regulatory documents do not detail any specific safety constraints or warnings unique to older adults.


Q: Is Folicard considered a blood thinner?

A: Folicard is classified as a hematopoietic agent (meaning it relates to blood cell formation) and a B-group vitamin. It is not classified as an anticoagulant or 'blood thinner' in official regulatory texts.


Q: Is Folicard available over the counter, or is it prescription-only?

A: Folic Acid, the active ingredient, is commonly available in both prescription and over-the-counter strengths and formulations. The specific availability of the branded product 'Folicard' may vary by region and strength.


Q: Are there generic versions of Folicard available?

A: Folic Acid, the active ingredient in Folicard, is a commonly used medication that is widely available as a generic product in various strengths.


Q: Can men take Folicard for the same reasons women do?

A: Yes. Folicard is used for treating conditions resulting from folate deficiency, which affects all humans. Official documents state that the requirement for folate is essential for nucleoprotein synthesis and maintaining normal blood production in 'man' (meaning humans).


Q: Does Folicard have an expiration date, and how strict is it?

A: Folicard must not be used past the printed expiry date on the package. Official guidance does not contain information on how strict the timeline is post-expiry, but the mandatory instruction is not to use the product once the expiration date has passed to ensure efficacy and stability.


Q: Is it normal to experience mild stomach upset when starting Folicard?

A: Gastrointestinal side effects such as nausea, abdominal distension, and flatulence have been reported in official product information. These effects are classified as rare or, in some cases, were noted in patients receiving a high daily dose of 15 mg.


Q: What should I do if I notice an unexpected skin reaction after taking Folicard?

A: Folicard is associated with rare instances of allergic responses, which can include skin rash, itching, and hives. Severe allergic reactions such as anaphylaxis and respiratory difficulty have also been reported. Adverse reactions and severe allergic responses are generally reported to a healthcare provider.


Q: Are there any known severe side effects associated with Folicard?

A: Although side effects are generally uncommon, rare instances of severe adverse reactions have been reported in official documents. These include serious allergic responses such as anaphylaxis (a severe, potentially life-threatening reaction) and severe respiratory difficulty due to bronchospasm.


Q: Can Folicard interact with herbal supplements?

A: Official guidance from regulatory bodies indicates that a healthcare provider should be informed before taking any herbal remedies or supplements together with Folicard. This is partly because certain vitamin and mineral supplements already contain Folic Acid, which could unintentionally increase intake.


Q: Do studies support Folicard's use for nerve function?

A: Official warnings note a critical connection between folate status and nerve function. Folicard is constrained from use alone in Vitamin B₁₂ deficiency because it can mask the hematological symptoms while allowing underlying neurological damage to progress. This warning highlights a significant physiological relationship between folate status and the nervous system.


Q: Is Folicard approved in other countries besides the US/EU?

A: Folic Acid is subject to regulatory oversight in many regions worldwide. This includes approval by major governmental agencies such as Health Canada, the Therapeutic Goods Administration (TGA) in Australia, and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.


Q: Are there documented cases of overdose with Folicard?

A: Official regulatory texts describe Folic Acid as relatively nontoxic in humans. Studies have been conducted that describe how the drug is excreted in the urine after very high doses. However, effects such as gastrointestinal upset and altered sleep patterns were reported at high daily doses (15 mg).


Q: Are there any specific warnings for people with diabetes taking Folicard?

A: Official warnings and precautions for Folicard do not list any specific safety constraints or notes unique to patients who have diabetes.


Q: Can Folicard cause changes in appetite?

A: Official product information associates Folicard with reported gastrointestinal side effects, including anorexia (loss of appetite). This effect was specifically noted in a study involving patients who were receiving a high daily dose of 15 mg for one month.

How should Folicard be stored and disposed of?

Official Storage and Disposal Instructions

Folicard (Folic Acid tablets) must be stored according to official regulatory requirements to ensure stability and safety.

Storage Requirement Official Guidance
Temperature Store at Controlled Room Temperature, typically 20 to 25 C (or below 25 C in some regions).
Protection Keep the tablets protected from light and moisture (store in a dry place).
Container Maintain the medicine in its original package to safeguard its integrity. Do not use the product past the printed expiry date.

Child-Safety and Disposal

It is a mandatory safety requirement to keep Folicard out of the sight and reach of children.

For disposal, do not throw away any unused or expired medicines via wastewater or household waste as it may impact the environment. You must consult a pharmacist for guidance on proper disposal procedures or utilize a drug take-back program where available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Folicard found in:

A-Z Index: